论文部分内容阅读
为确定从小牛肺提取的肺表面活性物质制剂开塞肺的药效及其剂量范围，对通过肺灌洗造成的豚鼠肺表面活性物质缺乏模型进行了实验研究，同时与德国同类制剂（Ａｌｖｅｏｆａｃｔ）作了对比。两制剂各剂量组用药后，肺顺应性及气体交换均显著改善（Ｐ＜０．０１），并呈现剂量依赖性。证明开塞肺对继发性肺表面活性物质缺乏性疾病是一有效制剂，３５ｍｇ／ｋｇ剂量已有显著治疗作用，高剂量效果优于低剂量，最适剂量约为１００ｍｇ／ｋｇ，与国外制剂无显著性差异。
In order to determine the efficacy and dose range of pulmonary surfactant preparations extracted from calf lung, the pulmonary surfactant-deficient model of guinea pig caused by pulmonary lavage was studied. At the same time, Made a contrast. After treatment, the lung compliance and gas exchange of both groups were significantly improved (P <0.01), and showed a dose-dependent manner. Proved that open plug lung pulmonary surfactant secondary deficiency is an effective preparation, 35mg / kg dose has a significant therapeutic effect, high-dose effect is better than low dose, the optimal dose of about 100mg / kg, and foreign agents No significant difference.